Skip to main content

Table 1 Baseline Characteristics

From: A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects

 

FKB327 vial

n = 66

FKB327 PFS

n = 63

FKB327 AI

n = 66

Total

n = 195

Age (years)

 Mean (SD)

38 (13.6)

40 (12.9)

37 (12.5)

38 (13.0)

Sex, n (%)

 Male

50 (75.8)

45 (71.4)

50 (75.8)

145 (74.4)

 Female

16 (24.2)

18 (28.6)

16 (24.2)

50 (25.6)

Race, n (%)

 Asian

2 (3.0)

4 (6.3)

3 (4.5)

9 (4.6)

 Black

2 (3.0)

1 (1.6)

9 (13.6)

12 (6.2)

 White

62 (93.9)

58 (92.1)

53 (80.3)

173 (88.7)

 Other

1 (1.5)

1 (0.5)

Weight (kg)

 Mean (SD)

76.2 (10.37)

75.2 (10.98)

75.5 (11.56)

75.6 (10.93)

BMI (kg/m2)

 Mean (SD)

25.2 (3.06)

25.2 (2.62)

24.8 (2.85)

25.1 (2.84)

  1. AI indicates prefilled autoinjector; BMI body mass index; PFS prefilled syringe; SD standard deviation; vial, vial with disposable syringe